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ABSTRACT 
 
        Parasitic diseases are a severe threat to people and animals. Praziquantel is the most 
common anti-parasitic drug with high efficiency, and it has been used to treat parasitic diseases 
for many years. However, it has very strong gastrointestinal and liver metabolism that leads to a 
strong first-pass effect and a short half-life. Additionally, the frequent oral administration was 
inconvenient for the large livestock. To overcome these drawbacks, this study aimed to develop 
an extended-release thermosensitive hydrogel formulation that was applicable to the injectable 
administration. The praziquantel-loaded hydrogel formulation based on poloxamer 407 (20%, 
w/v) was prepared, and two strategies for modifications of poloxamer 407 hydrogel were 
studied. One of them was the formulation consisting of PEG-DSPE/TPGS mixed micelles-
poloxamer 407 hydrogel hybrid system; another was the poloxamer 407 hydrogel adding with 
HPMC as an adhesive. These hydrogel formulations had a reversible sol-gel transition property 
at approximate 26 °C and obtained high loading efficiencies and storage stability. In-vitro release 
studies, as well as in-vivo pharmacokinetic studies, were conducted to evaluate the extended-
release effect, and the bioavailability of several optimized formulations of praziquantel was 
calculated. The in-vitro release of praziquantel was prolonged when loading into poloxamer 407 
hydrogel. Both the modifications of poloxamer 407 hydrogel, by adding HPMC as well as 
iii 
 
utilizing PEG- DSPE/TPGS mixed micelle as a secondary delivery vehicle obtained the 
relatively better extended-release profiles than the original poloxamer 407 hydrogel. The 
pharmacokinetic studies indicated that the poloxamer 407 hydrogel formulation has a relatively 
high bioavailability and prolonged release profile, but both two modifications failed to obtain a 
significant improvement of an extended-release characteristic compared with the original 
hydrogel solution.  
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I. INTRODUCTION 
 
         
        Parasitic diseases are a severe threat to people and animals, especially in tropical countries, 
sub-tropical countries and most agricultural countries. Schistosomiasis, caused by the infection 
from parasitic worms such as Schistosoma mansoni, Schistosoma haematobium, and 
Schistosoma japonicum, is a typically parasitic disease resulting in several chronic symptoms, 
and it has been considered the most severe helminthic disease in terms of high morbidity and 
mortality. Approximately 200 million people worldwide are affected by schistosomiasis, and 
almost 800 million people are at risk for schistosomiasis. 
        Praziquantel (Figure 1), which was discovered in 1975, is a broad- spectrum antiparasitic 
drug.  Owing to its high efficacy, praziquantel has been the most essential anti-parasitic drug for 
human and animals. It has been widely used for schistosomiasis treatment and other trematode 
infections or even cestode infections for several decades1,2. So far, the most widely available 
formulation of praziquantel on the market is the oral formulation, associated with the therapeutic 
regimen of 20 mg/kg, three times a day at intervals of 4–6 hours or as a single dose of 40 mg/kg. 
However, the bioavailability of the oral delivery of praziquantel   
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is extremely low because of the strong first-pass effect, which means about 99% of the drug is 
metabolized before entering to circulation3. The pharmacokinetic study demonstrates that the 
elimination half-life (t1/2) of praziquantel is  
 
                                                              Figure 1. Chemical structure of praziquantel 
 
between 1 and 1.5 h, and more than 90% drug will be eliminated within 24 h. The fast 
elimination of praziquantel and short mean residence time (MRT) lead to frequent dosing4,5. 
Additionally, frequent oral delivery of praziquantel is not convenient especially for the 
administration to the large livestock. Therefore, it is necessary to develop an injectable, 
extended-release formulation to improve the bioavailability of the drug and prolong the dosing 
intervals. 
        Poloxamer is a series of triblock copolymers consisting of a specific ratio of 
polyoxyethylene (PEO) and polyoxypropylene (PPO). Poloxamer 407, a widely used copolymer, 
has a molecular weight of 12 kDa containing 70% PEO units and 30% PPO unit6.  As the 
temperature increases, the poloxamer 407 molecule begins to self-assemble into micelles. This 
micellization is driven by the dehydration of the hydrophobic polyoxypropylene block that 
becomes progressively less soluble as the polymer concentration or temperature increases. The 
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aggregation of several monomers occurs to minimize the interactions of the PPO blocks with the 
solvent. Thus, the core of the aggregates is made from the insoluble blocks (polyoxypropylene) 
while the soluble portion (polyoxyethylene) forms the shell of the micelles. The hydrophobic 
drug is able to be encapsulated into hydrophobic PPO core while the existence of hydrophilic 
PEO moiety makes poloxamer well-dissolved in water. When the temperature sequentially 
increases over critical gelling temperature (CGT), the gelation consequently happens due to the 
ordered packing of micelles7 (Figure 2). Poloxamer 407 hydrogel aqueous solution possesses the 
reversible thermo-gelation property at the concentration of 20% or higher. Within the 
concentration of 20%-40%, the sol-gel transition temperature is lower than body temperature, it 
means after the injectable administration of cold, liquid-form hydrogel solution to the body (37 
°C), it will then become a semi-solid gel in a short time.  
        Poloxamer 407 hydrogel is a very suitable vehicle for drug delivery system owing to its low 
toxicity, high biocompatibility and high solubilizing capacity for the hydrophobic drugs8. 
Despite many advantages of poloxamer 407 hydrogel, it still has some limitations. The hydrogel 
structure is not able to maintain for a long time in physiological conditions. The network easily 
breaks down since the weak mechanical strength makes it susceptible to the dilution of 
poloxamer 407 by the influx of in-vivo water, which results in a burst release of the drug9. To 
modify the poloxamer 407 hydrogel for obtaining a better extended-release system, several 
strategies have been studied including 1) increasing the drug-hydrogel interactions by physically 
or covalently crosslinking method10. 2) increasing the viscosity and density of the gel network by 
physical mixing with some additives6 or by chemical grafting with polymeric materials11,12. 3) 
co-formulating particulate systems (such as micelles) as a secondary delivery vehicle into the 
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hydrogel matrix forming a composite hydrogel network13. Hydroxypropylmethylcellulose 
(HPMC) is a well-known mucoadhesive, and it has been demonstrated that the addition of 
HPMC to hydrogel solution is able to improve the extended-release profiles of the drug. Possibly 
HPMC reinforces the strength between each poloxamer 407 micelles, meanwhile, the net 
structure of poloxamer 407 hydrogel becomes denser, leading to an increased viscosity which 
prolongs the dissolution of the hydrogel as well as the drug release14 (Figure 3). 
        As stated above, loading the hydrophobic drug into the micelle-hydrogel hybrid system is 
also a promising strategy to modify the hydrogel-based formulation. If we first load the drug into 
a secondary delivery vehicle, such as micelles, then the drug is going to release from the 
secondary delivery vehicle and then release from the hydrogel network, consequently the release 
of drug from the micelle-hydrogel hybrid system will be prolonged (Figure 4). In our previous 
study, an efficient and versatile delivery system for the hydrophobic drug with the polymeric 
micelles consisting of PEG-DSPE and TPGS was developed. The conjugates of polyethylene 
glycol (PEG) and diacyl lipids, such as PEG-distearoylphosphatidylethanolamine (PEG-DSPE), 
formed stable micelle in which a number of sparingly water-soluble drugs could be incorporated. 
TPGS is a derivative of Vitamin E, which is obtained by conjugating PEG with Vitamin E 
succinate via the esterification reaction. TPGS is an amphiphilic polymer that has both the 
advantages of Vitamin E and PEG in applications of drug delivery. The previous studies showed 
that at a 1:2 molar ratio, PEG-DSPE/TPGS mixed micelles could encapsulate paclitaxel and 
tanespimycin (17-AAG) with high stability and efficiency, and the release of the drug was 
significantly prolonged16. 
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                     Figure 2. Schematic diagram to show the formation of poloxamer 407 hydrogel 
  
        The present study aimed to design an injectable formulation of praziquantel based on 
thermosensitive poloxamer 407 hydrogel, which was also able to obtain the extended-release 
characteristic. Two strategies for modifying the poloxamer 407 hydrogel were investigated. The 
in vitro release studies and in vivo pharmacokinetics studies were conducted, and the results 
demonstrated that the poloxamer 407 hydrogel formulation increased the water solubility of 
praziquantel as well as prolonged the release profile, and the bioavailability of the drug was 
significantly improved compared with oral delivery. Two modifications of hydrogel obtained 
better extended-profile during in vitro release study, but did not show significant improvement in 
the pharmacokinetic study. The possible reason was finally discussed. 
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              Figure 3. Schematic diagram to show the network structure of HPMC-added poloxamer 
407 hydrogel 
 
 
 
Figure 4. Drug releases from micelle-hydrogel dual system
 7 
 
II. MATERIAL AND METHOD 
 
 
Chemicals and instrumentation  
        Praziquantel was purchased from Sigma-Aldrich Chemical Company (USA). Poloxamer 
407 was a gift from BASF Chemical Company (US). 1,2-Distearoyl-sn-Glycerol-3-
Phosphoethanolamine-N- [Methoxy (Polyethylene glycol)-2000] (PEG-DSPE) was purchased 
from Corden Pharma (Cambridge, MA). D-α-Tocopheryl polyethylene glycol 1000 succinate 
(TPGS) was a gift from Eastman Chemical Company (Kingsport, TN). 
Hydroxypropylmethylcellulose (HPMC, E4M) was a gift from Dr. Michael A. Repka’s lab. 
Analyses were performed on an Agilent 1260 Infinity Analytical SFC System combined with an 
Agilent 1260 Infinity ELSD Evaporative Light Scattering Detector. Acetonitrile (ACN, HPLC 
grade) was purchased from Fisher scientific Chemical Company (US). 
 
Preparation of praziquantel incorporating PEG-DSPE/TPGS mixed micelles 
        The praziquantel-loaded mixed micelles were prepared using thin-film evaporation 
method16. Briefly, 10 mg TPGS, 10.2 mg PEG-DSPE and 1 mg praziquantel were dissolved in 
1.2 ml chloroform in a round -bottom flask, then the chloroform was removed under vacuum and
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dried overnight. The film was then hydrated with 100 µl 10 mM HEPES-buffered saline (PH 7.4) 
with vigorous vortexing for 5 min. The mixed solution was sonicated at room temperature for 10 
min, then it was centrifuged at 12,000 g for 5 min to form a clear micellar dispersion (PZQ/M). 
The micellar solution was kept at 4 °C. 
 
Preparation of praziquantel-incorporated PEG-DSPE/TPGS micelles-poloxamer 407 
hydrogel hybrid system 
        The poloxamer 407 hydrogel was prepared using ‘cold method’17. Briefly, poloxamer 407 
(20%, w/v) was added to cold water, then the mixed solution was kept at 4 °C with continuous 
stirring overnight to ensure the complete dissolution of poloxamer 407. Praziquantel-
incorporated micelle was slowly added to 1 ml hydrogel solution at 4 °C with gentle stirring. 
Finally, the sodium chloride (0.9 %, w/v) solution was added to obtain PZQ/M/P407 hydrogel 
solution (1mg/ml).  
 
Preparation of praziquantel loaded poloxamer 407 hydrogel and poloxamer 407/HPMC 
hydrogel 
        To make a comparison with the effect of the praziquantel-loaded micelle, 1mg praziquantel 
dissolved by ethanol was added to 1ml hydrogel solution using the same method described above 
to obtain PZQ/P407 hydrogel solution. For the preparation of praziquantel loaded poloxamer 
407/HPMC hydrogel, HPMC 1% (w/v) was first added to hot water, after the HPMC was 
completely swelled, it was shifted to 4 °C with continuous stirring until the solution became 
totally clear and transparent. Then 1 mg praziquantel dissolved by ethanol was slowly added to 1 
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ml poloxamer 407/HPMC hydrogel solution to obtain PZQ/P407/HPMC hydrogel solution (1 
mg/ml). All the hydrogel solutions were kept at 4 °C for further use. 
 
Measurement of Lower Critical Solution Temperature (LCST) and Gelation Time 
        The temperature and time of the sol-gel transition were determined using tube-inverting 
method18. For the testing of LCST, 500 µl hydrogel solution was added in a 1.7 ml Eppendorf 
tube under digital dry bath, heating from 20 °C to 37 °C at a rate of 0.5 °C /min. Each minute, 
the tube was inverted 180 ° to observe the hydrogel gelling behavior. The temperature when the 
hydrogel solution did not flow for 15 s was determined as LCST. For the determination of 
gelation time, 500 µl hydrogel solution was added in a 1.7 ml Eppendorf tube at room 
temperature, then it was instantaneously transferred to a water bath at 37 °C. The gelling 
behavior was observed every 30 s by the tube-inverting method. The time until the hydrogel 
solution did not flow for 10 s was determined as gelation time. 
 
Quantification of praziquantel by HPLC analysis 
        The method was developed on the instrument consisting of Agilent HP1260 HPLC system 
with UV detection. The separation was carried out on a reversed phase column Luna C18 (150 
mm × 3 mm, 2.5 µm particle size: PhenomenexTM, USA). α-naphthoflavone was used as the 
internal standard at a concentration of 2 µM, and the detection wavelength for praziquantel and 
α-naphthoflavone were 198 nm and 281 nm, respectively. The Column temperature was 30 °C. A 
gradient elution method of A: sodium phosphate buffer (20 mM, pH 3.0) and B: acetonitrile (0-9 
min 60% A, 9.1-16.5 min 40% A) was used for the analyses of the samples, and 50 µl sample 
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was injected into the column each time with the mobile phase at a flow rate of 0.5 ml/min. 
 
Calibration curves 
        The in vitro calibration curve was prepared by diluting praziquantel stock solution (10 mM) 
with mobile phase (acetonitrile/sodium phosphate buffer, 40:60) to varying concentration of 
praziquantel (0, 0.5, 1, 5, 10 and 20 µM), each sample was added with α-naphthoflavone at a 
fixed concentration of 2 µM. The plasma calibration curve was prepared using six plasma 
samples collecting from mice (50 µl each) spiked with the same concentration interval as above, 
α-naphthoflavone was added to each sample at the concentration of 2 µM. 
        The plasma samples were analyzed by protein precipitation method using organic solvent19. 
Acetonitrile (250 µl) was dropwise added at five times the volume of each plasma sample and 
fully vortexed for 5min, then centrifuged at 1200 g for 5min. The organic phase was removed by 
speed vacuum evaporation, then the residue was reconstituted with 60 µl mobile phase. The 
reconstituted solution was centrifuged at 12,000 g for 5min, then the supernatant was collected 
and injected to HPLC for analysis.  
 
In-vitro release studies 
        In-vitro release studies were performed using a membrane-less dissolution method (Figure 
5). The advantage of this model was that the hydrogel formulations were in direct contact with 
the release medium, and thus the formulation factors which affecting the drug release were able 
to be readily discerned20. For the studies of praziquantel release from different formulations, 0.5 
g PZQ/M/P 407 hydrogel solution, PZQ/P 407/HPMC hydrogel solution and PZQ/P407 
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hydrogel solution were added to the glass vials under water bath at 37 °C for 5min. After the 
completion of the sol-gel transition, 5 ml release medium (phosphate buffered saline, pH 7.4) 
containing SDS solution (0.5 %, w/v) was carefully added to a glass vial in the water bath, 
layering over the hydrogel. The entire release medium was removed at the predetermined time 
point and fresh release medium was changed to the glass vial. For the release study of the 
praziquantel-incorporated micelle, the 0.5 g micellar solution was added to a cylindrical dialysis 
tube (cellulose membrane), and the other steps were as same as the membrane-less dissolution 
method above. The removed release medium was subjected to HPLC analysis to determine the 
cumulative release amount of praziquantel.  
 
 
 
Figure 5. The schematic diagram of the membrane-less dissolution method 
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Pharmacokinetic study in mice 
        The mice were randomly divided into six groups (n=3), four groups of mice were 
administered with subcutaneous injection of the praziquantel-incorporated micelle, PZQ/M/P407 
hydrogel solution, PZQ/P407/HPMC hydrogel solution and PZQ/P407 hydrogel solution with 
the same dosage of 10 mg/kg, respectively. For the other two groups of mice, one group was 
administered free praziquantel which dissolved in DMSO (10 mg/kg) via the tail vein injection, 
and another group of mice was orally injected with praziquantel which was dissolved in ethanol, 
Tween 80 and phosphate buffer (1:2:7, v/v/v) mixed solution at a dosage of 60 mg/kg. After the 
subcutaneous injection, whole blood was collected via the retro-orbital bleeding at 30, 90 and 
150 min. The time points of collecting the blood after intravenous injection were 2, 15, 30, 60 
and 90 min, while for oral injection were 30, 60, 90 and 150 min. The blood sample was 
centrifuged at 4 °C (12,000 g, 5 min), then the plasma was obtained by collecting the 
supernatant. The plasma samples were stored at -20 °C for further analysis. The internal standard 
was added to the plasma samples at a concentration of 2 µM, then the samples were analyzed 
using the same method described before. 
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III. RESULTS AND DISCUSSION 
 
Encapsulation efficiency and storage stability  
        For praziquantel-loaded PEG-DSPE/TPGS micelles, the final transparent micellar solution 
contains 32 mM praziquantel, 200 mM PEG-DSPE and 400 mM TPGS. At a 1:2 molar ratio of 
PEG-DSPE and TPGS, the mixed micelle incorporated more than 90% of drug which indicated a 
high encapsulation rate. Both the PZQ/P407, PZQ/M/P 407 and PZQ/P 407/HPMC hydrogel 
solution provided more than 90% drug loading without any precipitation. Praziquantel 
concentration in the micelle dispersion remained practically unchanged (>95%) at 4 °C for one 
week, indicating that the drug-incorporated micelles were stable at 4 °C and can be stored for at 
least one week. Besides, the stability duration should be extended for a more viable formulation. 
Further study in order to increase storage stability should be conducted.  
 
Lower Critical Solution Temperature (LCST) and Gelation Time 
        To form a thermosensitive hydrogel, the percentage of poloxamer 407 should be 20% (w/v) 
or above, the gelling temperature was directly determined by the content of poloxamer 407 in the 
hydrogel solution. For the poloxamer 407 solution in which the concentration of poloxamer 407 
was lower than 20%, the polymeric solution flowed freely at body temperature (37 °C) and did
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not form gel at all. Generally, for poloxamer 407 at the concentration between 20%-30%, the 
viscosity increased after being taken out of the refrigerator, but still allowed the free flow of the 
polymer solution at room temperature, making the injection possible. But for the concentration 
of 30% poloxamer 407 or above, the gelation temperature was as low as about 14 °C, making 
injection very difficult. So only 20% (w/v) poloxamer 407 hydrogel solution was chosen in this 
study. The sol-gel transition of PZQ/M/P407 and PZQ/ P407 hydrogel solution happened when 
the temperature was higher than 26 °C and the corresponding gelling time is approximately 80 s. 
For PZQ/P407/HPMC hydrogel solution, the gelling temperature was also 26 °C but it took only 
40 s to form a gel (Figure 6). Potentially HPMC facilitated the packaging of poloxamer 407 
micelles, making the micellization much easier to occur, therefore it formed a gel more quickly. 
 
                                                        
Figure 6. The sol-gel transition of the hydrogel 
 
HPLC assay and calibration curves 
        The retention times of praziquantel and α-naphthoflavone were 8.9 min and 14.9 min, 
respectively (Figure 7). The linear ranges, for both the calibration curve of praziquantel in vitro 
and in plasma, were 0.5-20 µM (Figure 8). The mean recoveries of praziquantel in plasma at the 
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concentration of 0.5-20 µM including the internal standard in all cases were higher than 85%. 
The results reflected essentially 85% recovery from the spiked plasma and indicated the sample 
preparation procedure was not interfering. 
 
Figure 7. Chromatogram of the standard solution of praziquantel (10 µM) and the internal 
standard (α-naphthoflavone: 2 µM), with retention times of 8.9 min and 14.9 min, respectively. 
 
In vitro release study 
        The praziquantel release profiles from different hydrogel solutions were studied (Table 1). 
As shown in Figure 9, the release of praziquantel from poloxamer 407 hydrogel was much 
slower compared to the release of praziquantel from TPGS/PEG-DSPE mixed micelle, indicating 
the network structure consisting of small poloxamer 407 micelles of hydrogel formulation 
blocked  
 16 
 
         Figure 8. The calibration curves of praziquantel: in vitro (A); in plasma (B). 
 
the release of the drug more effectively. For the PZQ/P407/HPMC hydrogel, the praziquantel 
released much more slowly than poloxamer 407 hydrogel only, probably because the HPMC 
chains bridged the poloxamer micelles, leading to a more compact network structure consisting 
of interconnected micelles. The increasing of densification and viscosity of the hydrogel resulted 
in the extension of the drug release profiles21. The PZQ/M/P407 hydrogel obtained the most 
obvious extended-release characteristic compared to the other formulations, demonstrating it 
would take a much longer time for the drug to release from the micelle-hydrogel dual system. 
But there was a defect of the release study. The release medium was not under continuous 
stirring during the process of drug release. In this case, it may not be a homogeneous solution but 
forming a concentration gradient of the drug which released from the tested formulation, 
therefore the drug release profile here would be a little different from the ideal condition. 
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Figure 9. The release kinetics of praziquantel from PEG-DSPE/TPGS micelle and several 
hydrogel formulations 
 
 
Table 1. The release half-lives (t1/2, release) of praziquantel from PEG-DSPE/TPGS micelle and 
several hydrogel formulations 
Formulation t1/2, release (h) Goodness of fit (R
2) 
PEG-DSPE/TPGS micelle 1.45 0.9596 
PZQ/P407 hydrogel 5.5 0.9596 
PZQ/P407/HPMC hydrogel 9.47 0.9792 
PZQ/M/P407 hydrogel 10.45 0.9792 
 
Pharmacokinetics of praziquantel in mice 
        To explore the bioavailability of subcutaneous administration of praziquantel-loaded 
formulations, the mice treated by intravenous injection of free praziquantel were set as the 
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control group. As shown in Figure 10 A, the plasma concentration-time profile demonstrated that 
the subcutaneous injection of PZQ/P407 hydrogel formulation obtained a relatively high 
bioavailability (Table 2), and the drug elimination was much slower. The comparison of oral 
administration (60 mg/kg) and subcutaneous injection of PZQ/P407 hydrogel (10 mg/kg) was 
shown in Figure 10 B. Although the oral dosage of praziquantel was six times higher than the 
subcutaneous dosage of hydrogel formulation, the area under the curve (AUC) of oral delivery 
was remarkably lower than the PZQ/P 407 hydrogel, indicating either a strong first-pass effect of 
the drug or the drug was not completely soluble in the gastrointestinal tract after oral 
administration. As illustrated in Table 2, the absolute bioavailability of subcutaneous injection of 
the hydrogel formulation of praziquantel was approximately 20 folds higher than oral 
administration. To modify the PZQ/P407 hydrogel for a better-extended release property, the 
PZQ/M/P 407 hydrogel and PZQ/P407/HPMC hydrogel were tested. However, both two 
modified hydrogel formulation failed to obtain a significant improvement of extended-release 
characteristic. The possible reasons were discussed here: 1) for PZQ/M/P 407 hydrogel, the 
pharmacokinetics of the subcutaneous injection of praziquantel-incorporated PEG-DSPE/TPGS 
micelle was compared with the intravenous injection of free drug. The results showed that the 
drug elimination following subcutaneous injection of the micellar solution was almost as fast as 
the intravenous injection of free drug, indicating the drug release from the micelle was much 
faster than release from the poloxamer 407 hydrogel. It meant the latter would be the rate 
limiting step, the total release rate should be more dependent on the drug release from the 
hydrogel. Therefore, the introduction of micelle as the secondary delivery vehicle did not 
radically contribute to prolonging the drug release characteristic. 2) for PZQ/P407/HPMC 
hydrogel: The hydrophobic and hydrophilic drugs distributed in different domains of the 
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hydrogel. The hydrophobic drug tends to partition into the hydrophobic PPO domain, while the 
hydrophilic drug partition into the hydrophilic PEO domain. Drug molecules distributed in the 
hydrophilic domain released by diffusing through the hydrophilic channels, drug distributed in 
hydrophobic domain released by the hydrogel erosion. Possibly, despite HPMC reinforce the 
poloxamer 407 micelles, form a more compact and denser network, it may mainly affect outside 
hydrophilic domain, in that case, the release of the hydrophobic drugs from the internal 
hydrophobic pores of the hydrogel would not be significantly prolonged (Figure 11). 
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Figure 10. The pharmacokinetic profiles of the formulations. The comparison between 
intravenous injection of free drug and subcutaneous injection of PZQ/ P407 hydrogel (A); the 
comparison between oral delivery of praziquantel and subcutaneous injection of PZQ/ P407 
hydrogel (B); the comparison between PZQ-loaded micelle solution and several hydrogel 
formulations (C); the comparison of intravenous injection of free drug and subcutaneous 
injection of praziquantel-loaded micelle (D). 
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Figure 11. The schematic diagram of the drug distribution in the hydrogel and the drug release 
 
 
 22 
 
 
 
Table 2. The half-lives (t1/2), the area under the curves (AUC) and the bioavailability (F) of 
different routes or formulations for the administration of praziquantel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation t1/2 （h） AUC (µM*h) F (%) 
i.v. free praziquantel 0.321 355.615 100 
p.o. free praziquantel 0.333 35.85 2.1 
Praziquantel-loaded micelle 0.323 290.48 81.7 
PZQ/P 407 hydrogel 0.963 311.71 87.7 
PZQ/P 407/HPMC hydrogel 1.269 331.96 93.3 
PZQ/M/P 407 hydrogel 1.409 350.52 98.6 
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IV. CONCLUSION 
 
        The current study succeeded in preparing a thermosensitive hydrogel based on poloxamer 
407 for the extended-release of praziquantel with a high loading efficiency. The liquid hydrogel 
solution will easily form a semi-gel after administered into the body. The HPLC methodology 
and the plasma analysis procedures were well-developed with the linear calibration curves and a 
high recovery ratio, respectively. The model of in vitro release study can still be modified to 
maintain a ‘perfect sink condition’. 
        By the hydrogel formulation, the solubility of praziquantel was significantly increased, and 
both the results of in vitro release study and in vivo pharmacokinetic study suggested that the 
hydrogel formulation obtained a better extended-delivery of praziquantel. All the bioavailability 
of subcutaneous injection of the poloxamer 407-based hydrogel formulations were dramatically 
higher than oral administration. Owing to the convenience of the injectable administration to 
large livestock, the hydrogel-system formulations would be an alternative delivery strategy for 
praziquantel. However, although poloxamer 407 copolymers rapidly formed a semi-solid gel in 
vivo, the gel-like property was not able to maintain for a long time in physiological conditions 
due to the weak strength of the interconnecting poloxamer 407 micelles. In this study, the PEG-
DSPE/TPGS mixed micelle-poloxamer 407 hydrogel hybrid system and poloxamer 407/HPMC 
hydrogel formulation was prepared to overcome the limitation of the original poloxamer 407 
hydrogel. The results of in vitro release study indicated that both two modified hydrogel
 24 
formulations obtained a better extended-release characteristic of praziquantel. However, two 
modifications of hydrogel were not able to obtain a significantly extended-release profile, and 
the possible reasons were discussed. On the basis of these discoveries, other micelles or even 
other materials, which can be investigated as novel secondary delivery vehicles to modify the 
hydrogel. The further modification of poloxamer 407 hydrogel formulation which can obtain a 
better extended-release characteristic will be investigated in the future. 
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